Back to top
more

Urogen Pharma (URGN)

(Delayed Data from NSDQ)

$15.30 USD

15.30
392,005

-0.38 (-2.42%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $15.32 +0.02 (0.13%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for URGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Urogen Pharma [URGN]

Reports for Purchase

Showing records 21 - 40 ( 52 total )

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 21

12/12/2022

Company Report

Pages: 5

Jelmyto and UGN-102 Durability Data; 3Q22 Financials; Adjusting PT to $23

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 22

10/26/2022

Company Report

Pages: 5

UGN-102 Physician Receptivity and Market Size Look Solid; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 23

09/28/2022

Company Report

Pages: 5

Jelmyto In-Use Period Extension Authorized; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 24

08/15/2022

Company Report

Pages: 5

Jelmyto Sales In-Line; Expenses Controlled; 2Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 25

06/07/2022

Company Report

Pages: 5

Jelmyto Novel Administration Route Data; 1Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 26

03/22/2022

Company Report

Pages: 5

Financial Results Reported; Lowering PT to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 27

03/02/2022

Company Report

Pages: 5

UGN-301 Investigational New Drug Application Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 28

02/11/2022

Company Report

Pages: 5

UGN-102 Pivotal Trial Starts; New Jelmyto Delivery Option; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 29

01/18/2022

Company Report

Pages: 5

Jelmyto Sales Trajectory Remains Slow and Steady; Lowering PT to $34

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 30

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for URGN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 31

08/05/2021

Company Report

Pages: 5

Jelmyto Commercial Progress Continues; 2Q21 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 32

05/17/2021

Company Report

Pages: 5

Top-Line Miss, Bottom-Line Beat in 1Q21; Positive Jelmyto Dynamics; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 33

04/27/2021

Company Report

Pages: 5

Sales Trajectory Modulated; Balance Sheet Strength; Reducing PT to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 34

03/16/2021

Company Report

Pages: 4

Johns Hopkins Collaboration Inked Focusing on Brain Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 35

01/14/2021

Company Report

Pages: 5

Collaboration Established With High-Profile Cancer Center; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 36

11/18/2020

Company Report

Pages: 5

OPTIMA II Phase 2b Final Data; 3Q20 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 37

09/08/2020

Company Report

Pages: 5

APOLLO Phase 2 Failure Does Not Impact Our Thesis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 38

08/12/2020

Company Report

Pages: 5

Jelmyto Enters the Market; 2Q20 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 39

05/08/2020

Company Report

Pages: 5

1Q20 Financials Reported; Looking to Jelmyto Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Urogen Pharma

Industry: Medical - Biomedical and Genetics

Record: 40

04/17/2020

Company Report

Pages: 4

Estimate Tweaks; Anticipating Solid Jelmyto Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party
// eof